PCSK9抑制剂与依折麦布联合或不联合他汀治疗对心血管风险降低的影响:系统综述与网状Meta分析
本研究为网状Meta分析,纳入14项随机对照试验共83660名使用他汀的成人,比较依折麦布与PCSK9抑制剂对心血管结局的影响。在极高或高心血管风险成人中,加用依折麦布或PCSK9抑制剂可能减少非致死性心肌梗死和卒中,但在中低风险人群中获益很小或没有。
要点
- 在他汀基础上加用依折麦布或PCSK9抑制剂可降低极高/高心血管风险成人的非致死性心肌梗死和卒中。
- 中低心血管风险成人中,加用依折麦布或PCSK9抑制剂对心肌梗死和卒中获益很小或没有。
- PCSK9抑制剂联合他汀基础上加用依折麦布可能减少卒中,但心肌梗死减少未达最小重要差异。
核心结论
- 在极高或高心血管风险且接受最大耐受他汀治疗或不耐受他汀的成人中,依折麦布或PCSK9抑制剂可能减少非致死性心肌梗死和卒中,但在中低风险成人中无此获益。
研究设计与样本
- 网状Meta分析,检索Medline、EMBASE和Cochrane Library至2020年12月31日,纳入依折麦布和PCSK9抑制剂的随机对照试验,要求≥500例患者且随访≥6个月。
- 共纳入14项试验,评估83660名使用他汀的成人中依折麦布和PCSK9抑制剂的效果。
- 采用频率学固定效应网状Meta分析和GRADE评估证据确定性。
主要发现
- 他汀加依折麦布降低心肌梗死(RR 0.87,95%CI 0.80-0.94)和卒中(RR 0.82,95%CI 0.71-0.96),但不降低全因死亡(RR 0.99,95%CI 0.92-1.06)或心血管死亡(RR 0.97,95%CI 0.87-1.09)。
- 他汀加PCSK9抑制剂降低心肌梗死(RR 0.81,95%CI 0.76-0.87)和卒中(RR 0.74,95%CI 0.64-0.85),但不降低全因死亡(RR 0.95,95%CI 0.87-1.03)或心血管死亡(RR 0.95,95%CI 0.87-1.03)。
- 极高心血管风险成人中,加用PCSK9抑制剂可能减少心肌梗死(每1000人16例)和卒中(每1000人21例)(中至高等确定性);加用依折麦布可能减少卒中(每1000人14例),但心肌梗死减少(每1000人11例)未达最小重要差异(中等确定性)。
- 高心血管风险成人中,加用PCSK9抑制剂可能减少心肌梗死(每1000人12例)和卒中(每1000人16例)(中等确定性);加用依折麦布可能减少卒中(每1000人11例),但心肌梗死减少(每1000人8例)未达最小重要差异(中等确定性)。
- 中低心血管风险组中,他汀加用PCSK9抑制剂或依折麦布对心肌梗死和卒中获益很小或没有。
关键数值与推荐
- 主要结局包括非致死性心肌梗死、非致死性卒中、全因死亡和心血管死亡,报告相对危险度(RR)和每1000例治疗5年的绝对风险。
- 指南小组和系统综述作者设定心肌梗死的最小重要差异为每1000人12例,卒中为每1000人10例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the impact of ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on cardiovascular outcomes in adults taking maximally tolerated statin therapy or who are statin intolerant. DESIGN: Network meta-analysis. DATA SOURCES: Medline, EMBASE, and Cochrane Library up to 31 December 2020. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials of ezetimibe and PCSK9 inhibitors with ≥500 patients and follow-up of ≥6 months. MAIN OUTCOME MEASURES: We performed frequentist fixed-effects network meta-analysis and GRADE (grading of recommendations, assessment, development, and evaluation) to assess certainty of evidence. Results included relative risks (RR) and absolute risks per 1000 patients treated for five years for non-fatal myocardial infarction (MI), non-fatal stroke, all-cause mortality, and cardiovascular mortality. We estimated absolute risk differences assuming constant RR (estimated from network meta-analysis) across different baseline therapies and cardiovascular risk thresholds; the PREDICT risk calculator estimated cardiovascular risk in primary and secondary prevention. Patients were categorised at low to very high cardiovascular risk. A guideline panel and systematic review authors established the minimal important differences (MID) of 12 per 1000 for MI and 10 per 1000 for stroke. RESULTS: We identified 14 trials assessing ezetimibe and PCSK9 inhibitors among 83 660 adults using statins. Adding ezetimibe to statins reduced MI (RR 0.87 (95% confidence interval 0.80 to 0.94)) and stroke (RR 0.82 (0.71 to 0.96)) but not all-cause mortality (RR 0.99 (0.92 to 1.06)) or cardiovascular mortality (RR 0.97 (0.87 to 1.09)). Similarly, adding PCSK9 inhibitor to statins reduced MI (0.81 (0.76 to 0.87)) and stroke (0.74 (0.64 to 0.85)) but not all-cause (0.95 (0.87 to 1.03)) or cardiovascular mortality (0.95 (0.87 to 1.03)). Among adults with very high cardiovascular risk, adding PCSK9 inhibitor was likely to reduce MI (16 per 1000) and stroke (21 per 1000) (moderate to high certainty); whereas adding ezetimibe was likely to reduce stroke (14 per 1000), but the reduction of MI (11 per 1000) (moderate certainty) did not reach MID. Adding ezetimibe to PCSK9 inhibitor and statin may reduce stroke (11 per 1000), but the reduction of MI (9 per 1000) (low certainty) did not reach MID. Adding PCSK9 inhibitors to statins and ezetimibe may reduce MI (14 per 1000) and stroke (17 per 1000) (low certainty). Among adults with high cardiovascular risk, adding PCSK9 inhibitor probably reduced MI (12 per 1000) and stroke (16 per 1000) (moderate certainty); adding ezetimibe probably reduced stroke (11 per 1000), but the reduction in MI did not achieve MID (8 per 1000) (moderate certainty). Adding ezetimibe to PCSK9 inhibitor and statins did not reduce outcomes beyond MID, while adding PCSK9 inhibitor to ezetimibe and statins may reduce stroke (13 per 1000). These effects were consistent in statin-intolerant patients. Among moderate and low cardiovascular risk groups, adding PCSK9 inhibitor or ezetimibe to statins yielded little or no benefit for MI and stroke. CONCLUSIONS: Ezetimibe or PCSK9 inhibitors may reduce non-fatal MI and stroke in adults at very high or high cardiovascular risk who are receiving maximally tolerated statin therapy or are statin-intolerant, but not in those with moderate and low cardiovascular risk.
引用
- Khan SU, Yedlapati SH, Lone AN, et al. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. BMJ. 2022. PMID: 35508321. doi:10.1136/bmj-2021-069116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。